A Randomized Phase 1 Clinical Trial of a Respiratory Syncytial Virus and Human Metapneumovirus Combination Protein-Based Virus-like Particle Vaccine in Adults 60–75 Years of Age
Open Forum Infectious Diseases · 27.03.2025 · 12 (4)
DOI: 10.1093/ofid/ofaf160 ↗Kurz gefasst
Fachartikel in der Zeitschrift Open Forum Infectious Diseases, online erschienen am 13.03.2025. Verfasst von Craig Shapiro und 9 weiteren Autor:innen. Beteiligte Einrichtung: Cenexel RCA, Hollywood, Florida, USA. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Icosavax, AstraZeneca group.
Abstract (Originalsprache)
Background
Respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) are important causes of severe lower respiratory tract disease (LRTD) in adults ≥65 years of age. We report safety and immunogenicity for IVX-A12, a combination, protein-based virus-like particle (VLP) vaccine against RSV- and hMPV-associated LRTD.
Methods
This phase 1 trial (NCT05664334) randomized healthy adults 60–75 years of age to receive 1 intramuscular dose of IVX-A12 at low (75 µg RSV/75 µg hMPV), medium (75 µg RSV/150 µg hMPV), or high dose levels (75 µg RSV/225 µg hMPV) ± oil-in-water adjuvant MF59® (low and medium dose levels only), or placebo. Safety and immunogenicity were assessed through day 365 postvaccination.
Results
Overall, 140 participants received IVX-A12 (n = 117) or placebo (n = 23). Solicited adverse reactions (ARs) were transient, with mild to moderate severity; ARs were reported by 47.0% (n = 55/117) and 34.8% (n = 8/23) of IVX-A12 and placebo recipients, respectively. There were no vaccine-related serious adverse events. All IVX-A12 dose levels and formulations boosted preexisting RSV- and hMPV-specific neutralizing antibody (nAb) responses; from baseline to day 28, nAb titers against RSV A or B increased up to 4- or 3-fold, and nAb titers against hMPV A or B increased up to 5- or 4-fold, respectively. Neutralizing responses in IVX-A12 recipients through day 365 were maintained above or around baseline and exceeded those in placebo recipients.
Conclusions
IVX-A12 was well-tolerated and elicited RSV- and hMPV-specific antibody responses in adults 60–75 years of age. These data support the ongoing clinical development of the RSV/hMPV combination VLP vaccine IVX-A12.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cenexel RCA, Hollywood, Florida, USA.
- Icosavax, Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Seattle, Washington, USA.
ORCID-Profile: Niranjan Kanesa-Thasan
Förderung
- Icosavax
- AstraZeneca group
Zitieren
APA
Shapiro, C., Sánchez-Crespo, N., Ciarlet, M., Hourguettes, N., Wen, J., Rida, W., Price, J., Engram, A. E., Adams, E. M., & Kanesa-Thasan, N. (2025). A Randomized Phase 1 Clinical Trial of a Respiratory Syncytial Virus and Human Metapneumovirus Combination Protein-Based Virus-like Particle Vaccine in Adults 60–75 Years of Age. Open Forum Infectious Diseases, 12(4). https://doi.org/10.1093/ofid/ofaf160
Vancouver
Shapiro C, Sánchez-Crespo N, Ciarlet M, Hourguettes N, Wen J, Rida W, et al. A Randomized Phase 1 Clinical Trial of a Respiratory Syncytial Virus and Human Metapneumovirus Combination Protein-Based Virus-like Particle Vaccine in Adults 60–75 Years of Age. Open Forum Infectious Diseases. 2025;12(4). doi:10.1093/ofid/ofaf160
BibTeX
@article{Shapiro2025,
author = {Shapiro, Craig and Sánchez-Crespo, Nelia and Ciarlet, Max and Hourguettes, Nicholas and Wen, Judy and Rida, Wasima and Price, Jennifer and Engram, April E and Adams, Elizabeth M and Kanesa-Thasan, Niranjan},
title = {A Randomized Phase 1 Clinical Trial of a Respiratory Syncytial Virus and Human Metapneumovirus Combination Protein-Based Virus-like Particle Vaccine in Adults 60–75 Years of Age},
journal = {Open Forum Infectious Diseases},
year = {2025},
volume = {12},
number = {4},
doi = {10.1093/ofid/ofaf160}
}
EUVIMED